Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Shares of Denmark’s Novo Nordisk rose 3.5% to 613.30 kroner this morning, after the company reported better-than-expected net ...

Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.

The most anticipated annual report in Denmark does not disappoint. Denmark’s largest company and leading pharmaceutical ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.